Your browser doesn't support javascript.
loading
Japanese Society of Allergology task force report on standardization of house dust mite allergen vaccines - secondary publication.
Takai, Toshiro; Okamoto, Yoshitaka; Okubo, Kimihiro; Nagata, Makoto; Sakaguchi, Masahiro; Fukutomi, Yuma; Saito, Akemi; Yasueda, Hiroshi; Masuyama, Keisuke.
Afiliação
  • Takai T; Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Okamoto Y; Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Okubo K; Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Department of Head and Neck Sensory Organ Science (Otolaryngology), Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
  • Nagata M; Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Department of Respiratory Medicine, Saitama Medical University, Saitama, Japan; Allergy Center, Saitama Medical University, Saitama, Japan.
  • Sakaguchi M; Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Laboratory of Microbiology I, School of Veterinary Medicine, Azabu University, Kanagawa, Japan.
  • Fukutomi Y; Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan.
  • Saito A; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan.
  • Yasueda H; Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan.
  • Masuyama K; Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Department of Otorhinolaryngology-Head and Neck Surgery, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanas
Allergol Int ; 64(2): 181-6, 2015 Apr.
Article em En | MEDLINE | ID: mdl-25838095
BACKGROUND: In the 1990s, the Japanese Society of Allergology (JSA) standardized Japanese cedar pollen allergen vaccines. In the present study, the task force for house dust mite (HDM) allergen standardization of the Committee for Allergens and Immunotherapy of JSA reports the standardization of HDM allergen vaccines in Japan. METHODS: In vivo allergenic potency was determined by intradermal testing of 51 Japanese adults with positive serum specific IgE to HDM allergens. In vitro total IgE binding potency was analyzed by competition ELISA using a pooled serum, with sera obtained from 10 allergic patients. The amounts of HDM group 1 (Der 1) and group 2 major allergens in eight HDM allergen extracts were measured by sandwich ELISAs. Correlation between the in vitro total IgE binding potency and major allergen levels was analyzed. RESULTS: We selected a JSA reference HDM extract and determined its in vivo allergenic potency. The in vitro total IgE binding potency significantly correlated with Der 1 content, group 2 allergen content, and their combined amount, indicating that measurement of major allergen contents can be used as a surrogate in vitro assay. CONCLUSIONS: The task force determined the in vivo allergenic potency (100,000 JAU/ml) and Der 1 content (38.5 µg/ml) of the JSA reference HDM extract, selected the measurement of Der 1 content as the surrogate in vitro assay, and decided that manufacturers can label a HDM allergen extract as having a titer of 100,000 JAU/ml if it contains 22.2-66.7 µg/ml of Der 1.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Antígenos de Dermatophagoides / Imunoterapia Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Antígenos de Dermatophagoides / Imunoterapia Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2015 Tipo de documento: Article